Cargando…

Early and aggressive presentation of wild-type transthyretin amyloid cardiomyopathy: A case report

BACKGROUND: Wild-type transthyretin amyloidosis (ATTRwt) is the most common form of transthyretin amyloid cardiomyopathy, occurring mostly over age of 60 years (mean age of 80 years). Mean survival without treatment is 3.6 years, making early detection imperative. We report an unusual case of a 58-y...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boda, Ilham, Farhoud, Hassan, Dalia, Tarun, Goyal, Amandeep, Shah, Zubair, Vidic, Andrija
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808025/ https://www.ncbi.nlm.nih.gov/pubmed/36605423 http://dx.doi.org/10.4330/wjc.v14.i12.657

Ejemplares similares

Rare case of chronic Q fever myocarditis in end stage heart failure patient: A case report
por: Goyal, Amandeep, et al.
Publicado: (2022)

Cytomegalovirus infection in heart transplant patient presenting as appendicitis
por: Mancuso, Joseph, et al.
Publicado: (2023)

Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey
por: Nativi-Nicolau, Jose, et al.
Publicado: (2021)

Endomyocardial biopsy-proven hydroxychloroquine-induced cardiomyopathy in a patient with rheumatoid arthritis
por: Malhotra, Anureet, et al.
Publicado: (2023)

Multimodality Assessments of Wild-Type Transthyretin Amyloid Cardiomyopathy Presenting With Eccentric Hypertrophy and Aortic Regurgitation
por: Mori, Kazuya, et al.
Publicado: (2022)

Transcatheter aortic valve replacement for aortic insufficiency in a patient with aortic root Thrombus and left ventricular assist device: A risk worth taking?
por: Malhotra, Anureet, et al.
Publicado: (2023)

Endothelial Function Is Preserved in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Hashimoto, Yu, et al.
Publicado: (2023)

Diagnosis of Transthyretin Amyloid Cardiomyopathy
por: Hafeez, Adam S., et al.
Publicado: (2020)

Hereditary transthyretin amyloid cardiomyopathy
por: Zheng, Yiliang, et al.
Publicado: (2023)

Correlation Between Cardiac Images, Biomarkers, and Amyloid Load in Wild‐Type Transthyretin Amyloid Cardiomyopathy
por: Morioka, Mami, et al.
Publicado: (2022)

Clinical characteristics and natural history of wild‐type transthyretin amyloid cardiomyopathy in Japan
por: Yamada, Toshihiro, et al.
Publicado: (2020)

Progress in Cardiac Imaging Uncovers the Epidemiology of Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Dorbala, Sharmila, et al.
Publicado: (2021)

Wild-type transthyretin amyloid cardiomyopathy: expect the unexpected—a case report
por: Skov, Jens Kæstel, et al.
Publicado: (2023)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Speckle Tracking and Transthyretin Amyloid Cardiomyopathy
por: Rocha, Alexandre Marins, et al.
Publicado: (2017)

Systemic embolism in amyloid transthyretin cardiomyopathy
por: Vilches, Silvia, et al.
Publicado: (2022)

A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy
por: Huda, Ahsan, et al.
Publicado: (2021)

Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function
por: Nakano, Tomoya, et al.
Publicado: (2022)

Prognostic value of left atrial strain in patients with wild‐type transthyretin amyloid cardiomyopathy
por: Oike, Fumi, et al.
Publicado: (2021)

Usefulness of automatic assessment for longitudinal strain to diagnose wild-type transthyretin amyloid cardiomyopathy
por: Usuku, Hiroki, et al.
Publicado: (2023)

Clinical characteristics, outcome, and therapeutic effect of tafamidis in wild‐type transthyretin amyloid cardiomyopathy
por: Takashio, Seiji, et al.
Publicado: (2023)

Loperamide-induced cardiogenic syncope: a case report of a life-threatening presentation of an over-the-counter drug
por: Hegde, Vishwajit, et al.
Publicado: (2023)

Multi-modality imaging in transthyretin amyloid cardiomyopathy
por: Traynor, Bryan Paul, et al.
Publicado: (2019)

Standardising Care and Treatment of Transthyretin Amyloid Cardiomyopathy
por: Fontana, Marianna, et al.
Publicado: (2023)

Recovery of sinus rhythm by tafamidis in patients with wild-type transthyretin amyloid cardiomyopathy with atrial arrhythmias
por: Isotani, Yoshitaka, et al.
Publicado: (2022)

A simple staging system using biomarkers for wild‐type transthyretin amyloid cardiomyopathy in Japan
por: Nakashima, Naoya, et al.
Publicado: (2022)

Suspicion, screening, and diagnosis of wild‐type transthyretin amyloid cardiomyopathy: a systematic literature review
por: Bay, Katrine, et al.
Publicado: (2022)

Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy
por: Elliott, Perry, et al.
Publicado: (2021)

Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy
por: Falk, Rodney H., et al.
Publicado: (2021)

Transthyretin amyloid cardiomyopathy: An uncharted territory awaiting discovery
por: Porcari, Aldostefano, et al.
Publicado: (2020)

Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy
por: Nakamura, Makiko, et al.
Publicado: (2020)

Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden
por: Lauppe, Rosa Elisabeth, et al.
Publicado: (2021)

Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
por: Lauppe, Rosa, et al.
Publicado: (2022)

Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy
por: Nuvolone, Mario, et al.
Publicado: (2022)

Incidence and Predictors of Ventricular Arrhythmias in Transthyretin Amyloid Cardiomyopathy
por: Knoll, Katharina, et al.
Publicado: (2023)

Diagnosis of wild‐type transthyretin amyloid cardiomyopathy in Japan: red‐flag symptom clusters and diagnostic algorithm
por: Inomata, Takayuki, et al.
Publicado: (2021)

Reply to the letter to the editor
por: Hegde, Vishwajit, et al.
Publicado: (2023)

Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020)

Estimating the Gender Distribution of Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis
por: Kroi, Florint, et al.
Publicado: (2020)

Time-dependent change of relative apical longitudinal strain index in patients with wild-type transthyretin amyloid cardiomyopathy
por: Usuku, Hiroki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vhfp33sodeo4t8uoij3a9fiqc3